TLRY, US88688T2096

Tilray Medical wins Portugal testing approval for Tilray Brands stock

Published on 10/18/2026 at 12:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Tilray Medical received approval on October 13, 2026 for two in-house test categories. Tilray Brands stock follows revenue of USD 257.1 million.

Portugal approval and quarterly growth

Tilray Medical received INFARMED approval for in-house testing on October 13, 2026.
First-quarter fiscal 2027 revenue reached USD 257.1 million, up 23.00 percent year over year.
Tilray Brands had a market capitalization of USD 340.0 million as of October 16, 2026.

TLRY, US88688T2096, Illustration mit AI erstellt.

Tilray Brands, Inc. (ISIN US88688T2096) received a regulatory boost on October 13, 2026, when Portugal's INFARMED approved in-house testing at its Cantanhede medical-cannabis facility. The authorization covers microbiological and chemical or physical testing, according to Tilray.

Portugal approval targets release times

The new capability brings critical quality controls inside the EU-GMP-certified site instead of relying entirely on outside laboratories. Tilray said the change could reduce batch-release costs, shorten testing timelines and improve the movement of medical-cannabis products from harvest to sale.

The announcement matters because the Portugal platform is positioned as a supply base for regulated markets including Germany, the United Kingdom, Poland and Italy. The release described the authorization as a way to strengthen product control and support international distribution, rather than as a new sales contract.

Revenue grew while cannabis declined

Tilray's first fiscal quarter ended August 31, 2026, produced net revenue of USD 257.1 million, up 23.00 percent from USD 209.5 million a year earlier. Gross profit increased 35.00 percent to USD 77.5 million, while gross margin expanded to 30.00 percent from 27.00 percent, according to Tilray.

The mix remains important for investors. Beverage revenue rose 82.00 percent year over year to USD 101.5 million, while cannabis revenue fell to USD 56.1 million from USD 64.5 million. The quarter also produced a GAAP net loss of USD 40.0 million and operating cash flow of minus USD 16.5 million.

When is the next company date?

Tilray's next explicitly listed corporate date is the annual shareholder meeting on November 18, 2026, according to the company's investor-relations calendar. Its fiscal 2027 adjusted EBITDA guidance remains USD 68 million to USD 75 million for the year ending May 31, 2027.

Stock context stays risk-sensitive

Tilray Brands closed at USD 3.04 on Nasdaq on October 16, 2026 at 4:00 p.m. EDT. The market capitalization was USD 340.0 million, while the 52-week range was USD 3.03 to USD 16.20 on the same market-data snapshot.

The further course of trading is shown by the continuously updated real-time quote of TLRY stock.